Business

Roche announces donation of essential medicines and diagnostic solutions to the people affected by the devastating earthquake in Türkiye and Syria

Roche

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a donation to Türkiye and Syria with a total value of 1.5 million Swiss Francs. This includes medicines, other products and financial support. Among others, we are committed to donating 120,000 packages of Rocephin, a critical antibiotic used to treat the symptoms of many kinds of bacterial infections and listed on the World Health Organization's list of essential medicines.

2022 Otto Bayer Award goes to Professor Frank Glorius

Bayer

The Bayer Foundation has presented the Otto Bayer Award, complete with its prize money of 75,000 euros, to Professor Frank Glorius. The research scientist at the University of Münster received the award in recognition of the development of an extensive array of groundbreaking catalytic reactions for organic synthesis, facilitating the sustainable synthesis of organic molecules with high levels of selectivity and purity that offer outstanding value for medical and agricultural applications.

Pfizer reports record full-year 2022 results

Pfizer

Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance. Full-year 2022 revenues of $100.3 billion, an all-time high for Pfizer, reflecting 30% operational growth (excluding contributions from Paxlovid and Comirnaty, revenues grew 2% Operationally).

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

Bayer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus ADT in combination with docetaxel for marketing authorization in the European Union (EU) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above

Roche

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza. Post-exposure prophylaxis aims to prevent influenza in individuals following contact with someone infected with the influenza virus.

Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries

Pfizer

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has global rights on a not-for-profit basis to enable greater health for 1.2 billion people living in 45 lower-income countries.

Acquisition of Neogene Therapeutics completed

AstraZeneca

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts).

Neogene will operate as a wholly owned subsidiary of AstraZeneca, with operations in Amsterdam, the Netherlands and California, US.

Business

More Pharma News ...